Catalent, Inc

The past year yielded a downward trend across the board for dealmaking in the biopharmaceutical sector, regardless of which metric one looks at. In the area of mergers and acquisitions, deal volume, t

Throughout 2024, the acquisition of Catalent, one of the world’s biggest CDMOs, by Novo Holdings, the holding company for the global pharmaceutical giant Novo Nordisk, prompted much concern among big

Although 2024 got off to a promising start with a busy first quarter, the fourth quarter marked the third consecutive quarter of declining biopharma merger-and-acquisition valuation. Evaluate reported

In Vivo’s editors, along with experts from the wider Citeline team, have selected our top four picks for the most significant M&A, alliance and financing deals of 2024. Vote now in the polls belo